Barry Shuman, MD
Urology · Albany, NYNPI 1811964430
Payments from drug & device makers
Across 418 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$973
- Antares Pharma, Inc.$907
- AbbVie$707
- Johnson & Johnson$634
- Pfizer$580
- Urogen Pharma, Inc.$509
- plus $5K from 33 others
What the payments were for
- Food & beverage$9,11698%
- Education$1992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 43 | $973 |
| Antares Pharma, Inc. | 58 | $907 |
| AbbVie(2 entities) | 38 | $707 |
| Johnson & Johnson | 23 | $634 |
| Pfizer | 32 | $580 |
| Urogen Pharma, Inc. | 15 | $509 |
| Sumitomo Pharma America, Inc. | 21 | $480 |
| Merck | 20 | $466 |
| Myriad Genetic Laboratories, Inc. | 14 | $390 |
| Boston Scientific | 6 | $327 |
| Urovant Sciences Inc | 11 | $305 |
| 180 Medical, Inc. | 12 | $298 |
| Halozyme Inc | 13 | $266 |
| Teleflex LLC | 8 | $230 |
| Tolmar, Inc. | 11 | $208 |
| Ferring Pharmaceuticals Inc. | 7 | $205 |
| Myovant Sciences Inc. | 9 | $165 |
| Procept Biorobotics Corporation | 1 | $165 |
| Tolmar Pharmaceuticals, Inc. | 9 | $157 |
| Axonics, Inc. | 6 | $134 |
| Medtronic | 5 | $127 |
| Coloplast | 8 | $122 |
| Amgen | 5 | $121 |
| Endo Pharmaceuticals Inc. | 6 | $118 |
| Neotract Inc. | 6 | $102 |
| Hollister Incorporated | 5 | $92 |
| Bayer | 4 | $73 |
| Travere Therapeutics, Inc. | 3 | $66 |
| Endo USA, Inc. | 3 | $61 |
| Blue Earth Diagnostics | 2 | $57 |
| Tempus AI, Inc | 2 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $54 |
| Mission Pharmacal Company | 3 | $45 |
| Novartis | 1 | $26 |
| Zyla Life Sciences, Inc. | 1 | $23 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Rochester Medical Corporation | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$177
- AquaBeam Robotic System$165
- myRisk$150
- XYOSTED$126
- RYBREVANT$122
- CARVYKTI$122
- XTANDI$119
- GENERAL ONCOLOGY$105
How this compares
$9,315 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 37 | $528,088 |
| MyrbetriqMirabegron | 264 | $273,171 |
| GemtesaVibegron | 62 | $67,677 |
| XyostedTestosterone Enanthate | 33 | $36,978 |
| Tolterodine Tartrate ErTolterodine Tartrate | 140 | $22,302 |
| Tamsulosin Hcl | 977 | $15,306 |
| Mirabegron ErMirabegron | 15 | $13,479 |
| Solifenacin Succinate | 113 | $11,338 |
| Finasteride | 648 | $10,218 |
| Testosterone | 31 | $8,242 |
| Potassium Citrate ErPotassium Citrate | 67 | $7,680 |
| Silodosin | 80 | $7,546 |
| Methenamine Hippurate | 50 | $5,920 |
| Dutasteride | 149 | $4,360 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $2,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $973 | $801,259301 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $480 | $67,67762 claims |
| Antares Pharma, Inc.Xyosted | $907 | $36,97833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.
Other urology in Albany
- Badar MianAlbany$1.1M
- Ronald KaufmanAlbany$421K
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.